Harvard Bioscience, Inc.

Equities

HBIO

US4169061052

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 02:00:39 2024-05-22 pm EDT 5-day change 1st Jan Change
3.29 USD +0.61% Intraday chart for Harvard Bioscience, Inc. -2.46% -37.10%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Harvard Bioscience, Inc., Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q1 Revenue $24.5M MT
Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q1 EPS $0.02 MT
Harvard Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Harvard Bioscience, Inc. Provides Earnings Guidance for the Full Year 2024 CI
Harvard Bioscience Reducing Headcount MT
Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth CI
Harvard Bioscience, Inc. Enters into A Third Amendment to the Credit Agreement CI
Transcript : Harvard Bioscience, Inc., Q4 2023 Earnings Call, Mar 07, 2024
Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q4 Revenue $28.2M MT
Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q4 EPS $0.04 MT
Harvard Bioscience, Inc. Provides Revenue Guidance for the Full Year 2024 CI
Harvard Bioscience, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
North American Morning Briefing : Powell Still in -2- DJ
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications At Society of Toxicology Meeting CI
Transcript : Harvard Bioscience, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q3 Revenue $25.4M MT
Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q3 EPS $0.01 MT
HARVARD BIOSCIENCE INC - REMAIN ON PATH TO REDUCING NET LEVERAGE… RE
Harvard Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2023 CI
Harvard Bioscience, Inc. to Showcase Latest Innovations in Preclinical and Organoid Research At Society for Neuroscience Conference CI
Harvard Bioscience Unit Named as Exclusive Distributor of Etisense's Cardiorespiratory Monitoring Product MT
Insider Buy: Harvard Bioscience MT
Harvard Bioscience Seeks Acquisitions CI
Chart Harvard Bioscience, Inc.
More charts
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.27 USD
Average target price
7 USD
Spread / Average Target
+114.07%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW